Inicio>>Signaling Pathways>> DNA Damage/DNA Repair>> LIM Kinase (LIMK)>>TH-257

TH-257

Catalog No.GC38860

TH-257 es un potente inhibidor de LIMK1 y LIMK2 con valores IC50 de 84 nM y 39 nM para LIMK1 y LIMK2, respectivamente, y puede usarse como sonda quÍmica para LIMK1 y LIMK2. TH-257 es un inhibidor alostérico que se dirige a un bolsillo de uniÓn inducido por una conformaciÓn de salida de αC y DFG. TH257 es exquisitamente selectivo y no se ha observado actividad significativa contra el kinoma mÁs amplio en el ensayo KINOMEscan a 1 μM.

Products are for research use only. Not for human use. We do not sell to patients.

TH-257 Chemical Structure

Cas No.: 2244678-29-1

Tamaño Precio Disponibilidad Cantidad
5mg
42,00 $
Disponible
10mg
71,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

TH-257 is a potent inhibitor of LIMK1 and LIMK2 with IC50 values of 84 nM and 39 nM for LIMK1 and LIMK2, respectively, and it can be used as a chemical probe for LIMK1 and LIMK2. TH-257 is an allosteric inhibitor targeting a binding pocket induced by an αC and DFG-out conformation. TH257 is exquisitely selective and no significant activity against the wider kinome has been observed in the KINOMEscan assay at 1 μM[1].

[1]. Manetti F. Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials. Eur J Med Chem. 2018 Jul 15;155:445-458.

Reseñas

Review for TH-257

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TH-257

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.